Efaroxan

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C13H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G00490L21H, chemically known as (+-)-2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-2-imidazoline but generally known as efaroxan, which bears US NIH Compound Identifier 72016. European Medicines Agency schedules Efaroxan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06462MIG. The term EFAROXAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). EFAROXAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule efaroxan under HS 29349990 and SITC 51579. As of Q4 2014, EFAROXAN remains the US FDA Preferred Term for this commodity. Efaroxan bears US NLM identifiers UMLS ID C0058957 and NCI Concept Code C72923. SMILES: O1C(CC2C1CCCC2)(CC)C1=NCCN1.